Delving into the Latest Updates on BPR-30221616 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesNervous System DiseasesCongenital Disorders+ [2]

Active Indication

Transthyretin Amyloid CardiomyopathyAmyloid Neuropathies, Familial

Inactive Indication-

Originator Organization

Brilliant Pharmaceutical Co. Ltd.

Active Organization

Brilliant Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： >评估BPR-30221616注射液在健康受试者中单次给药的安全性和耐受性。次要目的： >评估BPR-30221616注射液在健康受试者中单次给药的药代动力学（PK）特征。 >评估BPR-30221616注射液在健康受试者中单次给药的血清转甲状腺素蛋白（TTR）水平。 >评估BPR-30221616注射液在健康受试者中单次给药的免疫原性。探索性目的： >评估BPR-30221616注射液在健康受试者中单次给药的血清维生素A和视黄醇结合蛋白水平。

[Translation]

Primary objectives: > To evaluate the safety and tolerability of a single dose of BPR-30221616 injection in healthy subjects. Secondary objectives: > To evaluate the pharmacokinetic (PK) characteristics of a single dose of BPR-30221616 injection in healthy subjects. > To evaluate the serum transthyretin (TTR) level of a single dose of BPR-30221616 injection in healthy subjects. > To evaluate the immunogenicity of a single dose of BPR-30221616 injection in healthy subjects. Exploratory objectives: > To evaluate the serum vitamin A and retinol binding protein levels of a single dose of BPR-30221616 injection in healthy subjects.

Start Date10 Jan 2025

Sponsor / Collaborator

Brilliant Pharmaceutical Co. Ltd.

100 Clinical Results associated with BPR-30221616

Login to view more data

100 Translational Medicine associated with BPR-30221616

Login to view more data

100 Patents (Medical) associated with BPR-30221616

Login to view more data

100 Deals associated with BPR-30221616

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Transthyretin Amyloid Cardiomyopathy	Phase 1	China	Brilliant Pharmaceutical Co. Ltd.	10 Jan 2025
Amyloid Neuropathies, Familial	IND Approval	China	Brilliant Pharmaceutical Co. Ltd.	31 Dec 2024